Vésale Bioscience, a Belgian biotech, created in 2018, is committed to developing personalized phage-based therapies to combat multi-resistant bacterial infections (AMR).
Faced with the growing threat of antimicrobial resistance (AMR), bacteriophages, also know as phages, offer a promising natural solution. This motivated the company to pioneer in the development of innovative, personalized and sustainable phage-based therapeutic solutions.
Already voted Europe’s most innovative life sciences start-up in 2021, Vésale Bioscience was awarded in January 2023, by the European Innovation Council (EIC), 1.8 million euros to encourage its research.
Vésale Bioscience has introduced a pioneering personalized phage therapy platform that delivers tailored treatment for individual bacterial infections within a rapid timeframe of less than 24 hours. This innovative platform is designed to swiftly address a patient’s specific bacterial infection with precision and efficiency.
Vésale Bioscience’s approach is based on four key pillars:
An ever-evolving phage collection
Vésale Bioscience’s phage library currently encompasses a diverse and significant spectrum, targeting multi-resistant ESKP* strains in Western Europe. This extensive coverage is established in collaboration with several key European hospitals covering the majority of European multi-resistant strains.
The first on-site, automated phagogram
Accessible to all hospital laboratories with standard equipment on their premises, this automated, easy-to-use device makes it possible to assess the sensitivity of bacteria to phages, thus facilitating the selection of the most appropriate treatment for the patient.
Phage production in compliance with Good Manufacturing Practices
Vésale Bioscience then produces the selected phages in compliance with Good Manufacturing Practices (GMP) from a constantly expanding phage bank.
A fast, efficient, and integrated supply chain to deliver standardized phages for personalized therapy
The provided by Vésale Bioscience solutions could be used with antibiotics for an effective combined treatment.
(*) Escherichia coli – Staphylococcus aureus – Klebsiella pneumoniae – Pseudomonas aeruginosa
The company has forged strategic partnerships with university researchers, KOLs (Key Opinion Leaders), hospitals, reference centres and industry to achieve this goal. The aim is also to make these therapies accessible to all patients, improving their health and quality of life.
For more information, sent an e-mail to email@example.com.